Dr. Jack Regan reports

LEXAGENE ANNOUNCES RESULTS OF ANNUAL GENERAL SHAREHOLDER'S MEETING

Lexagene Holdings Inc. has released the voting results of the company's 2020 annual general shareholders meeting held on Nov. 10, 2020, in Vancouver, B.C.

A total of 48,273,080 common shares were voted at the meeting, representing 42.26 per cent of the votes attached to all outstanding common shares of the company.

All matters presented for shareholder approval at the meeting were duly authorized and approved as follows:

• To set the number of directors to be elected at five;
• Election of directors;
• To reappoint Manning Elliot LLP, chartered professional accountants, as the company's auditors for the ensuing year;
• Increase the number of common shares available for conversion of restricted share units;
• Increase the number of common shares available for exercise of options.

Detailed voting results for the election of directors were as shown in the attached table.

Name                    Shares voted     For %    Shares withheld     Abstain %  

Dr. John (Jack) Regan     22,117,120     97.03            677,427          2.97
Daryl Rebeck              22,705,522     95.22          1,089,025          4.78
Thomas Richard Slezak     22,691,362     99.55            103,185          0.45
Dr. Manohar Furtado       22,717,615     99.66             76,932          0.34
Joseph Caruso             22,494,351     98.68            300,196          1.32

To be added to the Lexagene e-mail list, please subscribe on the company website.

About Lexagene Holdings Inc.

Lexagene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets, such as clinical research, agricultural testing and biodefence. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press go. The MiQLab system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR (polymerase chain reaction) assays onto the instrument to target any genetic target of interest.

We seek Safe Harbor.